Imunon, Inc. Available-for-sale Securities, Amortized Cost Basis
Imunon, Inc. (IMNN) had Available-for-sale Securities, Amortized Cost Basis of $1.68 million as of 2016-12-31, per its 10-Q filed 2017-05-12.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2017-05-12
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $1.68M.
- 2016-09-30: Available-for-sale Securities, Amortized Cost Basis $4.51M.
- 2016-06-30: Available-for-sale Securities, Amortized Cost Basis $2.16M.
- 2015-12-31: Available-for-sale Securities, Amortized Cost Basis $10.80M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2016-12-31 | $1.68M 10-Q · filed 2017-05-12 | |
| 2016-09-30 | $4.51M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $2.16M 10-Q · filed 2016-08-15 | |
| 2015-12-31 | $10.80M 10-Q · filed 2016-11-10 | |
| 2015-09-30 | $16.77M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $18.78M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $22.40M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $24.19M 10-K · filed 2016-03-30 | |
| 2013-12-31 | $37.20M 10-K · filed 2015-03-12 | |
| 2012-09-30 | $14.36M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $12.60M 10-Q · filed 2012-08-14 | |
| 2011-12-31 | $10.43M 10-Q · filed 2012-11-09 | $10.67M 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |